SECRETONEURIN

The missing link biomarker in cardiac testing

Welcome to CardiNor
– developing the missing link biomarker test for cardiovascular disease

CardiNor AS is a Norwegian biotech company recently established to handle the commercialization of Secretoneurin (SN), a new biomarker for cardiovascular disease (CVD).

Facts and figures

0
US cost on cardiovascular disease 3500 USD/sec.
0
One heart attac in US every 43 sec.

Latest news from CardiNor

Press release, 26.01.2023:
CardiNor enter into a distribution agreement with B.S.N. Biological Sales Network for the CE marked CardiNor Secretoneurin ELISA test

Read more

Press release, 10.01.2023:
CardiNor enter into a distribution agreement with Demeditec Diagnostics GmbH for the CE marked CardiNor Secretoneurin ELISA test

Read more

Featured in CLI 31.10.2022:
Secretoneurin: a potential complementary cardiovascular biomarker

Secretoneurin is a novel prognostic biomarker that may predict mortality in heart failure and the occurrence of ventricular arrhythmias. Clinical Laboratory International (CLI) caught up with Professor Torbjørn Omland (University of Oslo, Oslo, Norway) to find out more about it.

Read more

Contact Us

Send us an email and we'll get back to you, asap.